Get the Stockscreener App
0.00
33.64%
-0.0603
Paxmedica Inc stock is traded at $0.00, with a volume of 0.
It is down -33.64% in the last 24 hours and down -57.01% over the past month.
See More
Previous Close:
$0.0603
Open:
$0
24h Volume:
0
Relative Volume:
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-17.66M
P/E Ratio:
0.00
EPS:
-6.8879
Net Cash Flow:
$-9.32M
1W Performance:
-33.64%
1M Performance:
-57.01%
6M Performance:
-93.93%
1Y Performance:
-85.81%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.00
Paxmedica Inc Stock (PXMD) Company Profile
Compare PXMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PXMD
Paxmedica Inc
|
0.00 | 0 | 0 | -17.66M | -9.32M | -6.8879 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Paxmedica Inc Stock (PXMD) Latest News
Contrasting Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & PaxMedica (NASDAQ:PXMD) - Defense World
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Comparing Intra-Cellular Therapies (NASDAQ:ITCI) and PaxMedica (NASDAQ:PXMD) - Defense World
Kuvatris Therapeutics Renames, Cancels Shares Amid Restructuring - AInvest
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
PaxMedica announces board resignations amid transition - Investing.com
PaxMedica Announces Board Chairman Resignation Amid Transition - TipRanks
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data - ACCESS Newswire
PaxMedica Announces Resignation of Key Executives - TipRanks
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection - ACCESS Newswire
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - ACCESS Newswire
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - ACCESS Newswire
PaxMedica Secures Immediate Exercise of Warrants - ACCESS Newswire
PaxMedica, Inc. (PXMD) Stock Price, News, Quote & History - Yahoo
PaxMedica Secures Groundbreaking China Patent for Autism Treatment Breakthrough After 100 Years - Stock Titan
Autism Prevalence Surges Globally, Raising Concerns Among Healthcare Experts - FinancialContent
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K | Dow Theory Letters - FinancialContent
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Intensifying Efforts to Achieve Significant Program Milestones - FinancialContent
Researchers Say Brain ‘Overgrowth’ Could Contribute to Autism Development - FinancialContent
Silicon Valley - FinancialContent
PaxMedica (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher - Barchart.com
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Ensuring Access to Life-Saving Treatments - FinancialContent
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - Yahoo Finance
PXMD Stock Price and Chart — OTC:PXMD - TradingView
PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA - FinancialContent
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - Yahoo Finance
As Autism Cases Rise, Biopharma Springs Into Action - BioSpace
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 - GlobeNewswire
Malawi’s Health Ministry Seeks Emergency Access to PaxMedica’s IV Suramin - NAVLIN DAILY
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness - Yahoo Finance
Why Is PaxMedica (PXMD) Stock Up 93% Today? - InvestorPlace
PaxMedica Achieves Key Milestone in the Development of - GlobeNewswire
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - GlobeNewswire
PaxMedica Accelerates RSU Vesting for Top Executives - TipRanks
PaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASD - The Globe and Mail
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman - StreetInsider
HC Wainwright & Co. Initiates Coverage of PaxMedica (PXMD) with Buy Recommendation - Nasdaq
PaxMedica (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M - The Globe and Mail
Penny Stocks To Buy? 5 To Watch Right Now - PennyStocks.com
PaxMedica News of FDA Type-B Meeting Shared in Audio Broadcast - Yahoo Finance
PaxMedica (NASDAQ: PXMD) News of FDA Type-B Meeting Shared in Audio Broadcast - The Globe and Mail
PaxMedica Releases Q3 2023 Financial Report, Corporate Update - Yahoo Finance
What LIFW, PXMD, and NVOS have in common - StocksToTrade
Why Is PaxMedica (PXMD) Stock Up 95% Today? - InvestorPlace
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV) - FinancialContent
PaxMedica (NASDAQ: PXMD) to jump 1,700% todaypurely nominal and technical - Dhaka Tribune
PaxMedica Announces 1-for-17 Reverse Stock Split - Yahoo Finance
Thinking about buying stock in Nextplay Technologies, ABVC Biopharma, PaxMedica, Mustang Bio, or NXU Inc.? - MarketScreener
Why Is PaxMedica (PXMD) Stock Up Today? - TradingView
Paxmedica Inc Stock (PXMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.29%
Cap:
|
Volume (24h):